Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.
about
The Role of Biosimilars in Inflammatory Bowel Disease.Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.Biosimilars in Crohn's Disease and Ulcerative Colitis.A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists.Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.Subsequent entry biologics - opportunities and challenges.Position of the Canadian Association of Gastroenterology on subsequent entry biologics is challenged by biosimilar industry representatives.Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review.ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
P2860
Q37540190-9977818F-9EE6-404C-92BF-08351CE769B4Q38223249-1651E414-AACC-4328-BEC8-3FFDE8C25350Q38365041-56C1F338-4099-4CF5-A9AA-7B9C3D9CD4CAQ38586029-04FF2DC7-DC7B-491D-8C94-9C7C64399468Q38708927-540D471E-9456-4F20-8F11-DDA1BAD2AE0AQ38757671-47F1BED3-0D37-4C5F-8C84-570D0CEB7C30Q38937842-39CC7C42-4FAF-4A09-9C48-BD0CDCF32680Q39059388-BAF3E205-45BD-490B-A3E1-7A65B1BFD942Q40897367-47B12711-5633-4AD5-818D-B02C73644D7DQ42938420-928D88B3-85D2-41A5-AB45-FF6F7BB1C318Q42962750-1DE3A537-B9CF-4E12-AFAA-1494005DA179Q49979586-CDE4EB32-5B7C-4011-B36E-17F4785D66C7Q51280643-2BC7DF3A-3CB2-4468-A2F2-975AF8F5CD56
P2860
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Overview of subsequent entry b ...... on subsequent entry biologics.
@en
type
label
Overview of subsequent entry b ...... on subsequent entry biologics.
@en
prefLabel
Overview of subsequent entry b ...... on subsequent entry biologics.
@en
P2093
P2860
P356
P1476
Overview of subsequent entry b ...... on subsequent entry biologics.
@en
P2093
Alain Bitton
Brian Bressler
Charles N Bernstein
Harminder Singh
Richard N Fedorak
Shane M Devlin
P2860
P304
P356
10.1155/2013/327120
P407
P577
2013-10-01T00:00:00Z